Animal models in osteosarcoma

Frontiers in Oncology

Volumn 4 JUL, Issue , 2014, Pages

  Guijarro, Maria V ^a   Ghivizzani, Steven C ^a   Gibbs, C Parker ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Animal models; Conditional mouse models; Germ line mouse models; Osteosarcoma; p53; RB

Indexed keywords

CIXUTUMUMAB; PROTEIN P53; RAPAMYCIN; SORAFENIB;

ALLELE; ANIMAL MODEL; BIOLUMINESCENCE; CANCER PROGNOSIS; CANINE MODEL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FLUORESCENCE IMAGING; GENE CONTROL; GENE DELETION; GENETIC PREDISPOSITION; GENETICALLY ENGINEERED MOUSE STRAIN; HIBERNOMA; HUMAN; LIPOSARCOMA; LUNG METASTASIS; LYMPHOMA; MOLECULAR PATHOLOGY; NONHUMAN; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RADIATION; REVIEW; RHABDOMYOSARCOMA; XENOTRANSPLANTATION;

EID: 84904679299     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00189     Document Type: Review

References (86)

1. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer (2009) 125(1):229-34. doi: 10.1002/ijc.24320
2. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer (2009) 115(7):1531-43. doi:10.1002/cncr.24121
3. McKenna RJ, Schwinn CP, Higinbotham NL. Osteogenic sarcoma in children. CA Cancer J Clin (1966) 16(1):26-8.
4. Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res (2009) 152:467-78. doi:10.1007/978-1-4419-0284-9_27
5. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev (2014) 40(4):523-32. doi:10.1016/j.ctrv.2013.11.006
6. Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol (2010) 11(7):670-8. doi:10.1016/S1470-2045(10)70062-0
7. Picci P, Ferrari S, Bacci G, Gherlinzoni F. Treatment recommendations for osteosarcoma and adult soft tissue sarcomas. Drugs (1994) 47(1):82-92. doi:10.2165/00003495-199447010-00006
8. Sloet van Oldruitenborgh-Oosterbaan MM, Klein WR, Misdorp W. Differential diagnosis of non-healing 'fungal' patches in horses. Tijdschr Diergeneeskd (1994) 119(24):756-9.
9. Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 45(7):799-803. doi:10.1038/ng.2645
10. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet (2003) 145(1):1-30. doi:10.1016/S0165-4608(02)00848-8
11. Pasic I, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, Ray PN, et al. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Res (2010) 70(1):160-71. doi:10.1158/0008-5472.CAN-09-1902
12. Fletcher JA, Gebhardt MC, Kozakewich HP. Cytogenetic aberrations in osteosarcomas. Nonrandom deletions, rings, and double-minute chromosomes. Cancer Genet Cytogenet (1994) 77(1):81-8. doi:10.1016/0165-4608(94)90154-6
13. Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, Barany F, et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A (2003) 100(20):11547-52. doi:10.1073/pnas.1934852100
14. Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, et al. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res (1990) 50(24):7950-4.
15. Miller CW, Aslo A, Won A, Tan M, Lampkin B, Koeffler HP. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol (1996) 122(9):559-65. doi:10.1007/BF01213553
16. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res (1992) 52(22):6194-9.
17. Hansen MF, Koufos A, Gallie BL, Phillips RA, Fodstad O, Brogger A, et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A (1985) 82(18):6216-20. doi:10.1073/pnas.82.18.6216
18. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res (1994) 54(11):3042-8.
19. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (1986) 323(6089):643-6. doi:10.1038/323643a0
20. Maitra A, Roberts H, Weinberg AG, Geradts J. Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. Int J Cancer (2001) 95(1):34-8. doi:10.1002/1097-0215(20010120)95:1<34::AID-IJC1006>3.0.CO;2-V
21. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet (1996) 86(2):136-42. doi:10.1016/0165-4608(95)00216-2
22. Wei G, Lonardo F, Ueda T, Kim T, Huvos AG, Healey JH, et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer (1999) 80(2):199-204. doi:10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4
23. Misdorp W. Skeletal osteosarcoma. Animal model: canine osteosarcoma. Am J Pathol (1980) 98(1):285-8.
24. Selvarajah GT, Kirpensteijn J, van Wolferen ME, Rao NA, Fieten H, Mol JA. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. Mol Cancer (2009) 8:72. doi:10.1186/1476-4598-8-72
25. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics (2009) 10:625. doi:10.1186/1471-2164-10-625
26. Mueller F, Fuchs B, Kaser-Hotz B. Comparative biology of human and canine osteosarcoma. Anticancer Res (2007) 27(1A):155-64.
27. Rankin KS, Starkey M, Lunec J, Gerrand CH, Murphy S, Biswas S. Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma. Pediatr Blood Cancer (2012) 58(3):327-33. doi:10.1002/pbc.23341
28. Kirpensteijn J, Teske E, Kik M, Klenner T, Rutteman GR. Lobaplatin as an adjuvant chemotherapy to surgery in canine appendicular osteosarcoma: a phase II evaluation. Anticancer Res (2002) 22(5):2765-70.
29. Kirpensteijn J, Timmermans-Sprang EP, van Garderen E, Rutteman GR, Lantinga-van Leeuwen IS, Mol JA. Growth hormone gene expression in canine normal growth plates and spontaneous osteosarcoma. Mol Cell Endocrinol (2002) 197(1-2):179-85. doi:10.1016/S0303-7207(02)00269-1
30. Kirpensteijn J, Kik M, Rutteman GR, Teske E. Prognostic significance of a new histologic grading system for canine osteosarcoma. Vet Pathol (2002) 39(2):240-6. doi:10.1354/vp.39-2-240
31. Lascelles BD, Dernell WS, Correa MT, Lafferty M, Devitt CM, Kuntz CA, et al. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann Surg Oncol (2005) 12(12):1073-83. doi:10.1245/ASO.2005.01.011
32. Kirpensteijn J, Kik M, Teske E, Rutteman GR. TP53 gene mutations in canine osteosarcoma. Vet Surg (2008) 37(5):454-60. doi:10.1111/j.1532-950X.2008.00407.x
33. van Leeuwen IS, Cornelisse CJ, Misdorp W, Goedegebuure SA, Kirpensteijn J, Rutteman GR. P53 gene mutations in osteosarcomas in the dog. Cancer Lett (1997) 111(1-2):173-8. doi:10.1016/S0304-3835(96)04529-6
34. Johnson AS, Couto CG, Weghorst CM. Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog. Carcinogenesis (1998) 19(1):213-7. doi:10.1093/carcin/19.1.213
35. Levine RA, Fleischli MA. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. Vet Pathol (2000) 37(1):54-61. doi:10.1354/vp.37-1-54
36. Levine RA, Forest T, Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol (2002) 39(3):372-8. doi:10.1354/vp.39-3-372
37. Liao AT, McMahon M, London CA. Identification of a novel germline MET mutation in dogs. Anim Genet (2006) 37(3):248-52. doi:10.1111/j.1365-2052.2006.01415.x
38. Martin TJ, Ingleton PM, Underwood JC, Michelangeli VP, Hunt NH, Melick RA. Parathyroid hormone-responsive adenylate cyclase in induced transplantable osteogenic rat sarcoma. Nature (1976) 260(5550):436-8. doi:10.1038/260436a0
39. Ingleton PM, Coulton LA, Preston CJ, Martin TJ. Alkaline phosphatase in serum and tumour of rats bearing a hormone-responsive transplantable osteogenic sarcoma. Eur J Cancer (1979) 15(5):685-91. doi:10.1016/0014-2964(79)90142-7
40. Underwood JC, Melick RA, Loomes RS, Dangerfield VM, Crawford A, Coulton L, et al. Structural and functional correlations in parathyroid hormone responsive transplantable osteogenic sarcomas. Eur J Cancer (1979) 15(9):1151-8. doi:10.1016/0014-2964(79)90131-2
41. Bensted JP, Blackett NM, Lamerton LF. Studies on the development of radiation-induced bone tumours. Acta Unio Int Contra Cancrum (1959) 15:559-60.
42. Ek ET, Dass CR, Choong PF. Commonly used mouse models of osteosarcoma. Crit Rev Oncol Hematol (2006) 60(1):1-8. doi:10.1016/j.critrevonc.2006.03.006
43. Dass CR, Ek ET, Choong PF. Human xenograft osteosarcoma models with spontaneous metastasis in mice: clinical relevance and applicability for drug testing. J Cancer Res Clin Oncol (2007) 133(3):193-8. doi:10.1007/s00432-006-0157-x
44. Becher OJ, Holland EC. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res (2006) 66(7):3355-8. doi:10.1158/0008-5472.CAN-05-3827 discussion 8-9
45. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov (2006) 5(9):741-54. doi:10.1038/nrd2110
46. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer (2007) 7(9):645-58. doi:10.1038/nrc2192
47. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis (2000) 18(3):261-71. doi:10.1023/A:1006767007547
48. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res (2001) 61(9):3750-9.
49. Sampson VB, Gorlick R, Kamara D, Anders Kolb E. A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol (2013) 3:132. doi:10.3389/fonc.2013.00132
50. Kresse SH, Meza-Zepeda LA, Machado I, Llombart-Bosch A, Myklebost O. Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations. Cancer (2012) 118(2):558-70. doi:10.1002/cncr.26276
51. Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL Jr. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res (1993) 53(20):4890-5.
52. Crnalic S, Hakansson I, Boquist L, Lofvenberg R, Brostrom LA. A novel spontaneous metastasis model of human osteosarcoma developed using orthotopic transplantation of intact tumor tissue into tibia of nude mice. Clin Exp Metastasis (1997) 15(2):164-72. doi:10.1023/A:1018456911823
53. Yuan J, Ossendorf C, Szatkowski JP, Bronk JT, Maran A, Yaszemski M, et al. Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases. Cancer Invest (2009) 27(4):435-42. doi:10.1080/07357900802491477
54. Janeway KA, Walkley CR. Modeling human osteosarcoma in the mouse: from bedside to bench. Bone (2010) 47(5):859-65. doi:10.1016/j.bone.2010.07.028
55. Ng AJ, Mutsaers AJ, Baker EK, Walkley CR. Genetically engineered mouse models and human osteosarcoma. Clin Sarcoma Res (2012) 2(1):19. doi:10.1186/2045-3329-2-19
56. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 356(6366):215-21. doi:10.1038/356215a0
57. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 4(1):1-7. doi:10.1016/S0960-9822(00)00002-6
58. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol (1989) 9(9):3982-91.
59. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 119(6):861-72. doi:10.1016/j.cell.2004.11.006
60. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 119(6):847-60. doi:10.1016/j.cell.2004.11.004
61. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet (1994) 7(4):480-4. doi:10.1038/ng0894-480
62. Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature (1992) 359(6393):288-94. doi:10.1038/359288a0
63. VanKoevering KK, Williams BO. Transgenic mouse strains for conditional gene deletion during skeletal development. IBMS boneKEy (2008) 5:151-70. doi:10.1138/20080312
64. Mohseny AB, Hogendoorn PC, Cleton-Jansen AM. Osteosarcoma models: from cell lines to zebrafish. Sarcoma (2012) 2012:417271. doi:10.1155/2012/417271
65. Lin PP, Pandey MK, Jin F, Raymond AK, Akiyama H, Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis (2009) 30(10):1789-95. doi:10.1093/carcin/bgp180
66. Calo E, Quintero-Estades JA, Danielian PS, Nedelcu S, Berman SD, Lees JA. Rb regulates fate choice and lineage commitment in vivo. Nature (2010) 466(7310):1110-4. doi:10.1038/nature09264
67. Berman SD, Calo E, Landman AS, Danielian PS, Miller ES, West JC, et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A (2008) 105(33):11851-6. doi:10.1073/pnas.0805462105
68. Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev (2008) 22(12):1662-76. doi:10.1101/gad.1656808
69. Mutsaers AJ, Ng AJ, Baker EK, Russell MR, Chalk AM, Wall M, et al. Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA. Bone (2013) 55(1):166-78. doi:10.1016/j.bone.2013.02.016
70. Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE, et al. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol (2006) 172(6):909-21. doi:10.1083/jcb.200508130
71. Molyneux SD, Di Grappa MA, Beristain AG, McKee TD, Wai DH, Paderova J, et al. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest (2010) 120(9):3310-25. doi:10.1172/JCI42391
72. Logan M, Martin JF, Nagy A, Lobe C, Olson EN, Tabin CJ. Expression of Cre recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis (2002) 33(2):77-80. doi:10.1002/gene.10092
73. Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development (2006) 133(16):3231-44. doi:10.1242/dev.02480
74. Frendo JL, Xiao G, Fuchs S, Franceschi RT, Karsenty G, Ducy P. Functional hierarchy between two OSE2 elements in the control of osteocalcin gene expression in vivo. J Biol Chem (1998) 273(46):30509-16. doi:10.1074/jbc.273.46.30509
75. Thomas DM, Carty SA, Piscopo DM, Lee JS, Wang WF, Forrester WC, et al. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell (2001) 8(2):303-16. doi:10.1016/S1097-2765(01)00327-6
76. Kuijjer ML, Namlos HM, Hauben EI, Machado I, Kresse SH, Serra M, et al. mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. BMC Med Genomics (2011) 4:66. doi:10.1186/1755-8794-4-66
77. Weisstein JS, Majeska RJ, Klein MJ, Einhorn TA. Detection of c-fos expression in benign and malignant musculoskeletal lesions. J Orthop Res (2001) 19(3):339-45. doi:10.1016/S0736-0266(00)90020-2
78. Ruther U, Komitowski D, Schubert FR, Wagner EF. C-Fos expression induces bone tumors in transgenic mice. Oncogene (1989) 4(7):861-5.
79. Entz-Werle N, Choquet P, Neuville A, Kuchler-Bopp S, Clauss F, Danse JM, et al. Targeted apc;twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human disease. Transl Oncol (2010) 3(6):344-53. doi:10.1593/tlo.10169
80. Krimpenfort P, Ijpenberg A, Song JY, van der Valk M, Nawijn M, Zevenhoven J, et al. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature (2007) 448(7156):943-6. doi:10.1038/nature06084
81. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature (2001) 413(6851):86-91. doi:10.1038/35092592
82. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res (2001) 61(16):6234-8.
83. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 49(7):928-40. doi:10.1002/pbc.21078
84. Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol (2012) 30(1):78-84. doi:10.1200/JCO.2011.35.6329
85. Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol (2012) 23(2):508-16. doi:10.1093/annonc/mdr151
86. Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol (2012) 30(3):256-62. doi:10.1200/JCO.2011.37.4355